BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, CA that focuses on designing and developing novel targeted medicines for difficult-to-treat cancers. Its science-driven approach addresses specific oncogenic drivers to improve patient outcomes. The company’s two lead clinical assets are BH-30643, a first-in-class, macrocyclic, non-covalent, mutant-selective OMNI-EGFRTM inhibitor aimed at EGFR- or HER2-mutated non-small cell lung cancer, and BH-30236, a macrocyclic CLK inhibitor targeting relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome. BlossomHill plans to use fresh capital to accelerate clinical development of these programs and to progress its wholly owned pipeline of designed cancer medicines. Since inception, the company has raised a total of $257 million in equity funding, most recently via a Series B extension. No operating metrics such as revenue or patient enrollment figures were disclosed in the article.

Total raised

$255M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2025